Cordio Medical

Cordio Medical provides medical grade, groundbreaking solutions to monitor several health conditions by analyzing voice samples recorded in a simple smartphone app backed by sophisticated and proprietary algorithms allowing near real-time monitoring and early detection of condition deterioration. Using only patient speech, sampled via mobile device, the Cordio HearO™ can sense fluid accumulation related to CHF and alert healthcare professionals in real-time. This is the only non-invasive, easy to use medical grade, CHF monitoring device that offers patients and caretakers peace of mind and a true sense of control. Cordio Med's technologies are based on true speech signal processing technology, unique to each patient, augmented with machine learning capabilities. The system is patient-tailored, and is constantly learning the patient’s voice and providing personalized, seamless and effortless monitoring. Cordio’s goal is to identify and mitigate condition worsening by helping physicians prevent patient deterioration and hospitalization while keeping the patient involved and informed.

Cordio Medical has raised $19.28M in total funding across 6 rounds. The company is currently at the C stage. Key investors include Peregrine Ventures, Iron Nation, Hadasit.

Cordio Medical operates in Health Tech & Life Sciences, Digital Healthcare, Patient Remote Monitoring, with core technologies in Artificial Intelligence, Voice & Speech Recognition, Machine Learning, Platforms & Interfaces, Mobile, Data Storage, Cloud. Target customers: Healthcare & Life Sciences, Healthcare, Providers, Patients.

Cordio Medical is based in Yehonatan Netanyahu St 6, Or Yehuda, Israel, Center District.